Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
Research ArticleBasic Science Investigation

Synthesis and In Vivo Evaluation of p-18F-Fluorohippurate as a New Radiopharmaceutical for Assessment of Renal Function by PET

Vibhudutta Awasthi, Gopal Pathuri, Hrushikesh B. Agashe and Hariprasad Gali
Journal of Nuclear Medicine January 2011, 52 (1) 147-153; DOI: https://doi.org/10.2967/jnumed.110.075895
Vibhudutta Awasthi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gopal Pathuri
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hrushikesh B. Agashe
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hariprasad Gali
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

The molecular structure of p-18F-fluorohippurate (18F-PFH) is similar to that of p-aminohippurate, a gold standard for the measurement of effective renal plasma flow. The objective of this study was to investigate 18F-PFH as a new PET renal agent. Methods: 18F-PFH was synthesized by reacting N-succinimidyl-4-18F-fluorobenzoate (18F-SFB) with glycine at 90°C (pH 8) for 20 min. In vitro stability was determined by incubating 18F-PFH in fresh human plasma at 37°C for 60 min. In vivo stability was determined by high-performance liquid chromatography analysis of urine collected from a normal rat at 40 min after injection of 18F-PFH. The plasma protein binding and erythrocyte uptake were determined using plasma collected from a normal rat at 5 min after injection of 18F-PFH. The plasma clearance of 18F-PFH was determined using a single-injection clearance method in normal and probenecid-treated rats. Biodistribution studies were conducted in normal rats at 10 min and 1 h after injection of 18F-PFH. Dynamic PET/CT studies were conducted in normal rats injected with 18F-PFH. Results: In normal rats, the plasma clearance of 18F-PFH was 4.11 ± 1.09 mL/min/100 g, which reduced by approximately 50% (P = 0.03) to 2.01 ± 0.08 mL/min/100 g in probenecid-treated rats. About 45.3% of 18F-PFH was found to associate with plasma proteins in vivo in normal rats. Biodistribution studies of 18F-PFH in normal rats showed 72.1 ± 6.4 percentage injected dose and 88.6 ± 6.2 percentage injected dose, respectively, in urine at 10 min and 1 h after injection. The uptake in other organs was negligible. High-performance liquid chromatography analysis of urine collected from a rat at 40 min after injection of 18F-PFH indicated that it was excreted intact, with no metabolic products. Dynamic PET revealed a rapid clearance of 18F-PFH through the renal–urinary pathway. The PET-derived renograms revealed a time to peak activity of 3.0 ± 1.0 min. Conclusion: These combined results warrant further investigation of 18F-PFH as a radiopharmaceutical for the assessment of renal function by PET.

  • PET
  • radiopharmaceuticals
  • renal
  • ERPF
  • renal function
  • renogram

Clinical PET is capable of providing excellent spatial resolution and absolute quantitative measurements; however, its use in the assessment of renal function has not been explored in the clinical setting. A few research studies have been conducted for the assessment of renal perfusion and glomerular filtration rate by PET. The corresponding radiotracers included 15O-H2O, 13N-NH3, 82Rb-Rb+, 62Cu-Cu(II)pyruvaldehyde bis-(N-4-methylthiosemicarbazonato), and 62Cu-Cu(II)ethylglyoxal bis(thiosemicarbazone) for renal perfusion studies (1–3) and 68Ga-Ga-ethylenediaminetetraacetic acid, 55Co-Co-ethylenediaminetetraacetic acid, and 18F-F− for glomerular filtration rate studies (3–7). In addition to drawbacks such as cost and availability, the clinical use of these radiotracers is limited by problems such as a short 2-min decay half-life (15O-H2O) or the high affinity of 18F-F− toward bone, which is less than optimal in a renal imaging study. In this scenario, PET presents almost no competitive advantage over widely used planar γ-imaging for functional imaging of kidneys.

99mTc-diethylenetriamine pentaacetic acid (99mTc-DTPA)– and 99mTc-mercaptoacetyltriglycine (99mTc-MAG3)–based planar γ-imaging remain the nuclear imaging techniques of choice for the clinical evaluation of renal function and renography (8–13). 99mTc-DTPA is exclusively cleared from plasma by glomerular filtration, a property that makes it useful at estimating the glomerular filtration rate (8,9). However, its renal extraction efficiency is only 20% (the filtration fraction) (9), making the resultant images carry a low target-to-background ratio, especially in a dynamic acquisition of high frequency in patients with poor renal function. In comparison, 99mTc-MAG3 is almost exclusively cleared from plasma by tubular secretion, with a renal extraction efficiency approaching that of o-131I-iodohippurate (131I-OIH) (10,11). The higher renal extraction of 99mTc-MAG3 is responsible for the improved image quality as compared with that obtained from 99mTc-DTPA. At the same time, the clearance and renogram curves of 99mTc-MAG3 are similar to those of 131I-OIH, the gold standard, with less than ideal imaging characteristics.

In this article, we present our preclinical work toward the development of an 18F-based renal imaging radiopharmaceutical, the biologic properties of which (compared with 99mTc-MAG3) may be closer to 131I-OIH. We observed that the major metabolite of 4-18F-fluorobenzoic acid is excreted rapidly and exclusively in urine as p-18F-fluorohippurate (18F-PFH) (14). It is known that benzoic acid derivatives are converted in vivo into hippuric acid derivatives via the glycine-conjugation pathway in the liver (15,16). This observation prompted us to investigate the potential use of 18F-PFH as a PET renal agent. We report the synthesis and initial in vivo evaluation of 18F-PFH in a rat model.

MATERIALS AND METHODS

General

All chemicals obtained commercially were used without further purification. Ethyl 4-(trimethylammonium triflate)benzoate and N-succinimidyl-4-fluorobenzoate (SFB) were synthesized as previously reported (17,18). No-carrier-added 18F-F− was obtained from Midwest Medical Isotopes, Inc. Electrospray mass spectral analysis was performed by the University of Oklahoma Health Sciences Center Molecular Biology-Proteomics Facility. 1H-NMR spectral analysis was performed on a Varian Mercury VX-300 NMR Spectrometer at the University of Oklahoma NMR Facility. Sprague–Dawley (175–200 g) female rats were purchased from Charles River Laboratories International, Inc. Small-animal PET/CT was conducted in the University of Oklahoma Health Sciences Center College of Pharmacy Small Animal Imaging Facility using a Flex X-O/X-PET/CT scanner (Gamma Medica-Ideas). All animal studies were conducted in accordance with the protocols approved by the University of Oklahoma Health Sciences Center Institutional Animal Care and Use Committee.

Reversed-phase high-performance liquid chromatography (HPLC) analyses of 18F-labeled and nonradioactive analogs were performed on a Beckman System Gold HPLC equipped with a Beckman Model 126 pump, 166 absorption detector, and a Bioscan Model B-FC-300 radioactivity detector. HPLC solvents consisted of water containing 0.1% trifluoroacetic acid (solvent A) and acetonitrile containing 0.1% trifluoroacetic acid (solvent B). A Sonoma C18 (ES Industries; 10 μm, 10 nm [100 Å], 4.6 × 250 mm) column was used with a flow rate of 1.5 mL/min. The HPLC gradient system began with an initial solvent composition of 80% solvent A and 20% solvent B for 2 min, followed by a linear gradient to 0% solvent A and 100% solvent B in 15 min, after which the column was reequilibrated. The absorption detector was set at 254 nm.

Synthesis of PFH

SFB (12.5 mg, 52.7 μmol) in dimethylformamide (0.5 mL) and glycine (2 mg, 26.7 μmol) in dimethylformamide (0.5 mL) were reacted in the presence of diisopropylethylamine (50 μL) for 18 h at room temperature. The resultant PFH was purified by HPLC (retention time, 8:23 min) and lyophilized to give pure PFH as a white powder in a yield of 76% (4 mg). 1H-NMR (D2O, 300 MHz) δ (ppm) 3.99 (s, 2H), 7.09 (m, 2H), 7.70 (m, 2H). Electrospray mass spectrometry calculated m/z for C9H8FNO3: 197.2; found: 195.9 ([M − H]−).

Radiosynthesis of 18F-SFB

18F-SFB was synthesized in 1 pot manually by slight modifications to a previously reported procedure (19). 18F-F− (259–925 MBq) dissolved in water (1–2 mL) was added to a 5-mL V-shaped-bottom vial containing 250 μL of Kryptofix 222 (K222) (20 mg/mL in acetonitrile) and 50 μL of K2CO3 (20 mg/mL in water). The solvents were evaporated under a stream of nitrogen at 90°C. Azeotropic drying was repeated twice with 1-mL portions of acetonitrile to generate the anhydrous [K/K222]18F complex.

Ethyl 4-(trimethylammonium triflate)benzoate (5.0 mg) dissolved in anhydrous acetonitrile (1 mL) was added to the dried [K/K222]18F complex, and the reaction mixture was heated at 90°Csealed for 10 min to produce ethyl 4-18F-fluorobenzoate. The ethyl ester was subsequently hydrolyzed to tetrapropylammonium 4-18F-fluorobenzoate by adding 1 M tetrapropylammonium hydroxide (50 μL) and heating the reaction mixture at 90°C sealed for 5 min. Finally, N,N,N′,N′-tetramethyl-O-(N-succinimidyl) uronium hexafluorophosphate (12 mg) dissolved in acetonitrile (1 mL) was added, and the reaction mixture was heated at 90°C sealed for 10 min. The reaction mixture was passed through an Oro-Sep SCX cartridge (600 mg; ChromTech), a Sep-Pak Light Accell Plus QMA cartridge (130 mg; Waters), and a Sep-Pak Light Alumina N cartridge (130 mg; Waters) connected in series to remove the cationic and anionic organic impurities and unreacted 18F-F−. The cartridges were eluted with an additional 2.5 mL of acetonitrile. The solvent was removed under a stream of nitrogen at 90°C, and 18F-SFB was redissolved in ethanol (100 μL). The decay-corrected radiochemical yield was 68%–72%, starting from 18F-F− in 8 preparations. The radiochemical purity of 18F-SFB was more than 99%, as determined by HPLC.

Radiosynthesis of 18F-PFH

A solution (100 μL) of 0.5 M glycine in 0.1 M Na2HPO4 (pH 8.0) was added to the 18F-SFB solution and reacted at 90°C for 20 min. Normal saline (400 μL) was added to the reaction mixture. The 18F-PFH was purified by HPLC, and solvents were evaporated by purging nitrogen at 90°C. The dried HPLC–purified 18F-PFH was reconstituted in normal saline and passed through a 0.2-μm syringe filter. The decay-corrected radiochemical yield for the glycine conjugation was 91%–95%. The radiochemical purity of the final product was more than 99%, as determined by HPLC.

In Vitro Stability

A sample of 18F-PFH (∼3.7 MBq, 25 μL) dissolved in normal saline was added to 1 mL of freshly collected human plasma in a culture tube and incubated at 37°C. An aliquot of the serum sample (2 μL) was injected into an HPLC column at 1 h to analyze the stability of 18F-PFH in human plasma. The experiment was performed using 3 separate samples.

In Vivo Stability

A female Sprague–Dawley rat was anesthetized with 2% vaporized isoflurane and injected with a dose of approximately 3.7 MBq of 18F-PFH in 250 μL of normal saline via the tail vein. The rat was euthanized at 40 min after injection, the bladder containing the urine was carefully excised, and the urine was collected from the bladder. An aliquot of the urine sample (10 μL) was injected into an HPLC column to analyze the in vivo stability of 18F-PFH in the rat.

In Vivo Plasma Protein Binding (PPB) and Erythrocyte Uptake

Two normal female Sprague–Dawley rats (∼220 g) were anesthetized with 2% vaporized isoflurane and injected with a dose of approximately 8.5 MBq of 18F-PFH in 400 μL of normal saline via the tail vein. A sample of approximately 2.5 mL of blood was collected in a heparinized blood collection tube from each rat at 5 min after injection. The blood samples were immediately centrifuged for 5 min, and plasma samples were collected. The PPB was determined by an ultrafiltration membrane system (20,21). A sample of 1 mL of plasma was added to Millipore Centrifree ultrafiltration tubes (molecular weight cutoff, 30,000) prerinsed with 500 μL of phosphate-buffered saline containing a 5 mg/mL solution of PFH. The ultrafiltration tubes were centrifuged at 1,667g for 45 min, and the ultrafiltrate was collected. The radioactivities associated with the plasma samples (50 μL) and ultrafiltrate samples (50 μL) were recorded on a Cobra II automated γ-counter (Packard Instruments). The radioactivity counts were corrected for the background and decay during the counting. PPB was calculated as (1 − [ultrafiltrate counts/plasma counts]) × 100. Nonspecific membrane binding was evaluated by centrifuging 18F-PFH in normal saline and showed no significant (<0.5%) membrane binding.

The blood samples were placed in capillary tubes and centrifuged to determine the hematocrit. The concentration of radioactivity (counts/g) in the whole blood and red blood cell samples was determined. Percentage erythrocyte uptake was calculated as (counts/g in red blood cells × hematocrit)/(counts/g in whole blood). No correction was made for plasma trapped in the red blood cell samples. The PPB and erythrocyte uptake were reported as a mean value obtained from 2 rats.

Plasma Clearance

The plasma clearance of 18F-PFH was determined using a single-injection clearance method as described by Blaufox et al. (22). Four normal female Sprague–Dawley rats (230–280 g) were used for these studies. A femoral artery catheter was used for withdrawal of blood samples at various sampling points. The catheter consisted of a 47-mm tip made with light wall PTFE tube (28 gauge) attached to 20 cm of Tygon tubing (23 gauge). The rat was anesthetized with 2% isoflurane in oxygen. The inside of the left thigh was shaved and disinfected. A 1-cm incision was made at the juncture of the abdomen and thigh. The femoral artery was isolated by blunt dissection and then irrigated with a few drops of 1% lidocaine. A section of artery (5–8 mm) was elevated, and a vertical slit was made by a sterile sharp blade. A catheter was placed inside the artery and tied to and secured against the thigh muscle. The catheter was flushed with a 20 U/mL solution of heparin–saline.

First, a probenecid-treatment study was performed, followed by a control study after 5 d of the first study on the same rats. During the 5-d waiting period, the femoral artery catheter was maintained with a heparin block and capped with a 23-gauge plug. Every second day, the catheter was flushed with saline, and the heparin block was reestablished. For the probenecid-treatment study, each rat was injected with probenecid (70 mg/kg) in 390 μL of normal saline through the tail vein under isoflurane anesthesia at approximately 10 min before injection of 18F-PFH (2.4–3.0 MBq) in 240–450 μL of normal saline. For the control study, each rat was injected only with a dose of 18F-PFH (2.4–3.0 MBq) in 240–450 μL of normal saline through the tail vein under isoflurane anesthesia. Blood samples of approximately 200 μL were collected at 2, 5, 10, 20, 30, 40, 50, and 60 min after injection of 18F-PFH. Blood samples were collected through the femoral artery catheter in heparinized tubes. Blood samples were centrifuged for 5 min, and 50 μL of plasma were separated. The radioactivity associated with each plasma sample was counted on the automated γ-counter.

All of the plasma samples were decay-corrected, background-subtracted, and plotted on a semilogarithmic graph as radioactivity (counts per minute/mL) against time (min) in Excel (Microsoft). The terminal portion (40, 50, and 60 min time points) of each curve was fitted with a single component, which was subtracted from the early portion (2, 5, and 10 min time points) of the curve to yield a more rapid early component. Clearance was calculated from the plasma curve by the method of Sapirstein et al. (23):Clearance(C)=Dose×b1b2Ab2+Bb1,where A and b1 are the intercept and slope, respectively, of the terminal slow component, and B and b2 are the intercept and slope, respectively, of the early rapid component of the plasma disappearance curve. This equation is based on a 2-compartment model in which the dose is injected into compartment 1, diffuses into compartment 2, and is excreted from compartment 1.

Biodistribution

Eight normal female Sprague–Dawley rats (200–220 g) were initially anesthetized with 2% isoflurane in oxygen at 2 L/min and injected with a dose of approximately 1.3 MBq of 18F-PFH in 200 μL of normal saline via the tail vein. Rats were kept under anesthesia during the study with 1% isoflurane in oxygen at 2 L/min. The rats were euthanized at 10 min (4 rats) and 1 h (4 rats) after injection. The bladder (containing the urine) and the tissue and organ samples were excised. The urine was collected from the bladder in a counting tube. If a rat urinated during or before euthanization, then the urine was carefully absorbed onto an absorbent gauze sponge and added to the corresponding urine tube. The tissues and organs were washed with normal saline, dried by blotting on tissue paper, and transferred to preweighed tubes. The tissue and organ sample tubes were weighed again to obtain the sample weight. The radioactivity associated with each sample tube was measured on the automated γ-counter. An undiluted standard dose (10 μL) was counted along with the samples. The radioactivity counts (counts per minute) were corrected for the background and radioactive decay. The percentage injected dose (%ID) and %ID/g of each tissue and organ were calculated. The %ID in blood was estimated assuming a whole-blood volume of 6.5% of the total body weight. The radioactivity in the stomach and intestines includes their content.

Small-Animal PET/CT

Five normal female Sprague–Dawley rats (200–220 g) were anesthetized initially using 2% isoflurane in oxygen at 2 L/min, in a polypropylene induction chamber. When fully anesthetized, the animal was placed on the scanner bed, with a nose cone used to maintain anesthesia at 1% isoflurane in oxygen at 2 L/min. Body temperature was maintained at 37°C using a water-circulated pad under the animal. A dose of approximately 2.6 MBq of 18F-PFH in 250 μL of normal saline was injected into the tail vein. Dynamic small-animal PET data were acquired over a period of 60 min after injection, followed by the acquisition of CT data over a period of 1 min. The PET data were reconstructed using a 2-dimensional filtered backprojection algorithm. The PET scan time was divided into ten 30-s time frames for the first 5 min, followed by a 30-s time frame at each 5-min interval (total, 21 frames for a total scan time of 60 min). Regions of interest (ROIs) were drawn over the kidneys and a subrenal background guided by CT images. Radioactivity within the ROIs of each frame was calculated. Radioactivity in kidney ROIs for each frame was decay-corrected and background-corrected using the subrenal background ROI. The time–activity curve of both kidneys (renogram) was plotted from the kidney ROI activities in each frame. Renogram analysis was performed for each rat. The time to peak activity and time to half-maximal activity were averaged for left and right kidneys for each rat. The right kidney fraction for each rat was calculated by dividing the counts in the right kidney ROI by the sum of counts in both right and left kidney ROIs at peak activity.

Statistical Analysis

All results are expressed as the mean ± SD. To determine the statistical significance of differences between the 2 groups, comparisons were made with the 2-tailed Student t test for paired data; a P value of less than 0.05 was considered to be statistically significant.

RESULTS

Chemistry

Nonradioactive PFH was synthesized to use as a reference standard for characterizing radioactive 18F-PFH by HPLC. PFH was characterized by electrospray mass spectrometry and 1H-NMR spectroscopy. Both PFH and 18F-PFH were synthesized using the same glycine conjugation reaction but with different conditions. The 18F-SFB prosthetic group was synthesized as shown in Figure 1, by slight modifications to the literature procedure (19). The HPLC retention times of 18F-SFB (radioactive detection) and cold SFB (ultraviolet detection) were identical, indicating the product formation. 18F-SFB was quantitatively converted to 18F-PFH using a 0.5 M glycine solution. The HPLC retention times of 18F-PFH (radioactive detection) and cold PFH (ultraviolet detection) were identical, indicating the product formation as shown in Figure 2.

FIGURE 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1.

Radiosynthesis of 18F-PFH.

FIGURE 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 2.

High-performance chromatograms of cold PFH (A), 18F-PFH (B), and rat urine (C) collected at 40 min after injection of 18F-PFH. No metabolic products were observed in urine. p.i. = after injection.

In vitro stability studies of 18F-PFH in human plasma at 37°C indicated that it is stable over the tested period of 1 h, and no degradation products were observed. For the in vivo stability study, we collected only a urine sample from a rat injected with 18F-PFH because it is excreted exclusively via the renal route. Figure 2 shows a typical high-performance chromatogram of the 18F-PFH injected dose and urine sample collected at 40 min after injection. No metabolites of 18F-PFH were detected in the urine sample, indicating that 18F-PFH is also stable in vivo.

Biology

The PPB of 18F-PFH was 45.3%, and erythrocyte uptake of 18F-PFH was 16.5%. The plasma clearance of 18F-PFH was 4.17 ± 1.13 mL/min/100 g in normal (control) rats, which reduced by approximately 50% (P = 0.034) to 2.06 ± 0.05 mL/min/100 g in probenecid-treated rats.

The biodistribution of 18F-PFH in normal rats at 10 min and 1 h after injection is shown in Table 1. The blood clearance was rapid, with only 3.54% ± 0.14% and 0.31% ± 0.18% of the injected dose remaining in the blood at 10 min and 1 h after injection, respectively (Table 1). The activity of 18F-PFH excreted in urine at 10 min and 1 h after injection was 72.1 ± 6.4 %ID and 88.6 ± 6.2 %ID, respectively (Table 1). Less than 0.5 %ID of 18F-PFH was found to be collectively associated with the blood, heart, lungs, liver, and spleen at 1 h after injection (Table 1).

View this table:
  • View inline
  • View popup
TABLE 1

Biodistribution of 18F-PFH in Rats at 10 Minutes and 1 Hour After Injection

Renograms

Results from the PET-derived renograms obtained after 18F-PFH administration in normal rats are summarized in Table 2. A representative renogram is shown in Figure 3. Average time to peak kidney activity was 3.0 ± 1.0 min, and average time to half-maximal activity was 5.6 ± 2.4 min. The average fraction of radioactive counts in the right kidney at peak maximum was 0.51 ± 0.06.

View this table:
  • View inline
  • View popup
TABLE 2

Renogram-Derived Data from Normal Rats Injected with 18F-PFH

FIGURE 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 3.

Kidney time–activity curves (renogram) from normal rat injected with 18F-PFH (∼2.6 MBq).

DISCUSSION

Noninvasive diagnostic procedures using radionuclides have been important in nuclear medicine practice for close to 3 decades (24). In classic physiologic imaging of renal function, glomerular filtration and tubular secretion are separately addressed by 99mTc-DTPA and 99mTc-MAG3, respectively (25). 99mTc-MAG3 has replaced the older 131I-OIH that served as an imaging analog for the most original tubular compound p-aminohippurate (PAH) (25,26). One of the goals in the radiopharmaceutics of renal agents has been to closely mimic the most original compound. For example, recently Taylor et al. have developed a new renal agent, 99mTc(CO)3(NTA), which demonstrated pharmacokinetic properties and renogram parameters essentially identical to those of 131I-OIH in healthy humans (27). The structural and functional similarity of 131I-OIH to PAH made 131I-OIH the imaging gold standard for tubular function assessment. The relative advantages and disadvantages of these agents, and the reasons for the acceptability of 99mTc-MAG3 as a clinical tubular agent, are well reviewed (11,13,28). While working on an unrelated project, we found that intravenously administered 4-18F-fluorobenzoic acid was excreted rapidly and exclusively in urine as 18F-PFH (14). This observation, as well as the structural similarity of 18F-PFH to PAH, prompted us to investigate 18F-PFH as a potential PET renal agent. Therefore, we developed an efficient radiosynthesis method for preparing 18F-PFH, as shown in Figure 1. 18F-PFH demonstrated high stability with no metabolic degradation in both in vitro and in vivo conditions (Fig. 2). Thus, 18F-PFH satisfies one of the important requirements for a renal agent—that is, no metabolic transformation in the body.

The PPB of 18F-PFH was comparable to that of 131I-OIH (45.3% vs. 44%, respectively), as reported in the literature (21). However, the erythrocyte uptake of 18F-PFH was lower than that of 131I-OIH (16.5% vs. 35%, respectively), as reported in the literature (21), which may be an advantage over 131I-OIH because of lower background. The plasma clearance of 18F-PFH was 4.11 ± 1.09 mL/min/100 g in normal rats, which is higher than the clearance of 125I-OIH (2.11 mL/min/100 g) in normal rats observed by Blaufox et al. (determined using a single-injection clearance method (22)). However, the clearance of 18F-PFH is comparable to that of 131I-OIH (3.36 mL/min/100 g) and 99mTc-MAG3 (4.73 mL/min/100 g) in normal rats reported by Eshima et al., calculated from 3 clearance periods after reaching steady-state blood levels (20). Other studies report 131I-OIH plasma clearance of 2.17 mL/min/100 g (29) and 2.96 mL/min/100 g (21); the plasma clearance of 99mTc-MAG3 has been reported as 2.84 mL/min/100 g in normal rats (29). The source of variability in the reported values of 131I-OIH and 99mTc-MAG3 plasma clearance is unknown. The plasma clearance of 18F-PFH was reduced by approximately 50% in probenecid-treated rats. The reduced plasma clearance of 18F-PFH in rats pretreated with probenecid demonstrates that renal excretion of this new agent may be principally by active tubular transport. Because the molecular structure of 18F-PFH is similar to that of PAH, 18F-PFH is likely transported by the same renal organic anion transporter 1 as PAH and 99mTc-MAG3 (30). As in PAH, the carbonylglycine (-CO-NH-CH2-COOH) side chain of 18F-PFH may enable an efficacious fit with the receptor proteins of the tubular transport system (31).

So that its plasma clearance would provide an accurate measurement of renal function, a renal agent must be exclusively excreted via the renal–urinary pathway to be used in humans. In this regard, 18F-PFH displayed a rapid clearance from the blood exclusively through the renal–urinary pathway, with minimal retention (0.58 ± 0.30 %ID) in the kidneys at 1 h after injection (Table 1). The blood clearance and excretion of activity in urine of 18F-PFH in normal rats are comparable to those of 131I-OIH (0.27 ± 0.16 %ID vs. 0.5 ± 0.0 %ID, respectively, in blood and 88.6 ± 6.2 %ID vs. 91.4 ± 3.7 %ID, respectively, in urine at 1 h after injection) as reported by Lipowska et al. (21). It is also important that the renal agent should not be cleared via the hepatobiliary pathway, to eliminate the high background activity in patients with impaired renal function. In this regard, the collective activity of 18F-PFH in the intestine and liver was less than 0.7 %ID at 1 h after injection (Table 1), suggesting that the hepatobiliary clearance of 18F-PFH is minimal.

The small-animal dynamic PET performed on normal rats with 18F-PFH indicated that the radiotracer was rapidly taken up by the kidney and cleared into bladder. Dynamic PET data were used to generate renograms (Fig. 3). The renogram data (Table 2) obtained here for 18F-PFH are similar to those available in the literature for 131I-OIH, further validating the functional similarity of 18F-PFH to 131I-OIH (32). One of the ideal characteristics of any 131I-OIH replacement would be that the radiotracer is not fixed to the renal tissue, as can be evaluated by comparing the peaks of the time–activity curves (renograms) and the analyses of transit times (33). The time to peak kidney concentration for 18F-PFH in normal rats was about 3 min (Table 2). This value is comparable to that reported for 131I-OIH in a normal rat (34). After reaching the peak kidney concentration, the time to excrete 90% of the accumulated 18F-PFH was about 12.5 min after injection. The PET/CT images presented in Figure 4 show the high uptake of radioactivity by the kidneys and its clearance into the urine or bladder within 30 min after injection, also confirming the exclusive renal excretion of 18F-PFH. At 60 min after injection, the radioactivity was completely cleared from all other organs except the bladder.

FIGURE 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 4.

Lower abdominal maximum-intensity-projection PET/CT images of normal rat injected with 18F-PFH (∼2.6 MBq). Within a few seconds of injection, radioactivity accumulated in kidneys, followed by start of its accrual in bladder within 2 min. By 30 min, almost all injected dose was excreted into bladder.

CONCLUSION

An efficient radiosynthesis method was developed for preparing 18F-PFH using a classic 18F-SFB prosthetic group. 18F-PFH demonstrated high stability, with no metabolic degradation in either in vitro or in vivo conditions. The PPB of 18F-PFH was found to be comparable to that of 131I-OIH as reported in the literature, with relatively lower erythrocytic uptake. Initial biodistribution and dynamic PET studies in normal rats revealed a rapid clearance of 18F-PFH exclusively through the renal–urinary pathway. The plasma clearance of 18F-PFH was reduced by approximately 50% in probenecid-treated rats, suggesting that renal excretion may be principally by renal tubular secretion. These combined results warrant further investigation of 18F-PFH as a radiopharmaceutical for the assessment of renal function by PET.

Acknowledgments

We gratefully acknowledge the expert technical assistance of Sandra S. Bryant and Kaustuv Sahoo during animal studies. We thank Midwest Medical Isotopes, Inc., Oklahoma City, Oklahoma, for generously providing 18F-F−. This work was funded by a University of Oklahoma College of Pharmacy startup grant and by Presbyterian Health Foundation Seed Grant C5046801.

  • © 2011 by Society of Nuclear Medicine

REFERENCES

  1. 1.↵
    1. Killion D,
    2. Nitzsche E,
    3. Choi Y,
    4. Schelbert H,
    5. Rosenthal JT
    . Positron emission tomography: a new method for determination of renal function. J Urol. 1993;150:1064–1068.
    OpenUrlPubMed
  2. 2.
    1. Shelton M,
    2. Green M,
    3. Mathias C,
    4. Welch M,
    5. Bergmann S
    . Assessment of regional myocardial and renal blood flow with copper-PTSM and positron emission tomography. Circulation. 1990;82:990–997.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Green MA,
    2. Mathias CJ,
    3. Willis LR,
    4. et al
    . Assessment of Cu-ETS as a PET radiopharmaceutical for evaluation of regional renal perfusion. Nucl Med Biol. 2007;34:247–255.
    OpenUrlCrossRefPubMed
  4. 4.
    1. Yamashita M,
    2. Inaba T,
    3. Kawase Y,
    4. et al
    . Quantitative measurement of renal function using Ga-68-EDTA. Tohoku J Exp Med. 1988;155:207–208.
    OpenUrlCrossRefPubMed
  5. 5.
    1. Goethals P,
    2. Volkaert A,
    3. Vandewielle C,
    4. Dierckx R,
    5. Lameire N
    . 55Co-EDTA for renal imaging using positron emission tomography (PET): a feasibility study. Nucl Med Biol. 2000;27:77–81.
    OpenUrlCrossRefPubMed
  6. 6.
    1. Schnöckel U,
    2. Reuter S,
    3. Stegger L,
    4. et al
    . Dynamic 18F-fluoride small animal PET to noninvasively assess renal function in rats. Eur J Nucl Med Mol Imaging. 2008;35:2267–2274.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Szabo Z,
    2. Xia J,
    3. Mathews WB,
    4. Brown PR
    . Future direction of renal positron emission tomography. Semin Nucl Med. 2006;36:36–50.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Gates G
    . Glomerular filtration rate: estimation from fractional renal accumulation of 99mTc-DTPA (stannous). AJR. 1982;138:565–570.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Barbour GL,
    2. Crumb CK,
    3. Boyd CM,
    4. Reeves RD,
    5. Rastogi SP,
    6. Patterson RM
    . Comparison of inulin, iothalamate, and 99mTc-DTPA for measurement of glomerular filtration rate. J Nucl Med. 1976;17:317–320.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Esteves FP,
    2. Taylor A,
    3. Manatunga A,
    4. Folks RD,
    5. Krishnan M,
    6. Garcia EV
    . 99mTc-MAG3 renography: normal values for mag3 clearance and curve parameters, excretory parameters, and residual urine volume. AJR. 2006;187:W610–W617.
    OpenUrl
  11. 11.↵
    1. Itoh K
    . 99mTc-MAG3: review of pharmacokinetics, clinical application to renal diseases and quantification of renal function. Ann Nucl Med. 2001;15:179–190.
    OpenUrlCrossRefPubMed
  12. 12.
    1. Taylor A Jr.,
    2. Eshima D,
    3. Fritzberg AR,
    4. Christian PE,
    5. Kasina S
    . Comparison of iodine-131 OIH and technetium-99m MAG3 renal imaging in volunteers. J Nucl Med. 1986;27:795–803.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Baert A,
    2. Sartor K,
    3. Schiepers C
    1. Jamar F,
    2. Barone R
    . Renal imaging. In: Baert A, Sartor K, Schiepers C, eds. Diagnostic Nuclear Medicine. Heidelberg, Germany: Springer; 2006:83–100.
  14. 14.↵
    1. Pathuri G,
    2. Agashe HB,
    3. Awasthi V,
    4. Gali H
    . Radiosynthesis and in vivo evaluation of a F-18-labeled pancreatic islet amyloid inhibitor. J Labelled Comp Radiopharm. 2010;53:186–191.
    OpenUrl
  15. 15.↵
    1. Mulder GJ
    1. Hutt AJ,
    2. Caldwell J
    . Amino acid conjugation. In: Mulder GJ, ed. Conjugation Reactions in Drug Metabolism. London, U.K.: Taylor and Francis Ltd.; 1990:273–305.
  16. 16.↵
    1. Tremblay GC,
    2. Qureshi IA
    . The biochemistry and toxicology of benzoic acid metabolism and its relationship to the elimination of waste nitrogen. Pharmacol Ther. 1993;60:63–90.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Guhlke S,
    2. Coenen HH,
    3. Stöcklin G
    . Fluoroacylation agents based on small n.c.a. [18F]fluorocarboxylic acids. Appl Radiat Isot. 1994;45:715–727.
    OpenUrlCrossRef
  18. 18.↵
    1. Vaidyanathan G,
    2. Zalutsky MR
    . Synthesis of N-succinimidyl 4-[18F]fluorobenzoate, an agent for labeling proteins and peptides with 18F. Nat Protoc. 2006;1:1655–1661.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Tang G,
    2. Zeng W,
    3. Yu M,
    4. Kabalka G
    . Facile synthesis of N-succinimidyl 4-[18F]fluorobenzoate ([18F]SFB) for protein labeling. J Labelled Comp Radiopharm. 2008;51:68–71.
    OpenUrlCrossRef
  20. 20.↵
    1. Eshima D,
    2. Taylor A Jr.,
    3. Fritzberg AR,
    4. Kasina S,
    5. Hansen L,
    6. Sorenson JF
    . Animal evaluation of technetium-99m triamide mercaptide complexes as potential renal imaging agents. J Nucl Med. 1987;28:1180–1186.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Lipowska M,
    2. Marzilli LG,
    3. Taylor AT
    . 99mTc(CO)3-nitrilotriacetic acid: a new renal radiopharmaceutical showing pharmacokinetic properties in rats comparable to those of 131I-OIH. J Nucl Med. 2009;50:454–460.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Blaufox MD,
    2. Guttmann RD,
    3. Merrill JP
    . Measurement of renal function in the rat with single injection clearances. Am J Physiol. 1967;212:629–632.
    OpenUrlFREE Full Text
  23. 23.↵
    1. Sapirstein LA,
    2. Vidt DG,
    3. Mandel MJ,
    4. Hanusek G
    . Volumes of distribution and clearances of intravenously injected creatinine in the dog. Am J Physiol. 1955;181:330–336.
    OpenUrlFREE Full Text
  24. 24.↵
    1. HE W,
    2. Fischman AJ
    . Nuclear imaging in the genitourinary tract: recent advances and future directions. Radiol Clin North Am. 2008;46:25–43.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Russell CD,
    2. Dubovsky EV
    . Measurement of renal function with radionuclides. J Nucl Med. 1989;30:2053–2057.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    1. Blaufox MD
    . Procedures of choice in renal nuclear medicine. J Nucl Med. 1991;32:1301–1309.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Taylor AT,
    2. Lipowska M,
    3. Marzilli LG
    . 99mTc(CO)3(NTA): a 99mTc renal tracer with pharmacokinetic properties comparable to those of 131I-OIH in healthy volunteers. J Nucl Med. 2010;51:391–396.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    1. Taylor AT,
    2. Lipowska M,
    3. Hansen L,
    4. Malveaux E,
    5. Marzilli LG
    . 99mTc-MAEC complexes: new renal radiopharmaceuticals combining characteristics of 99mTc-MAG3 and 99mTc-EC. J Nucl Med. 2004;45:885–891.
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    1. Fritzberg AR,
    2. Kasina S,
    3. Eshima D,
    4. Johnson DL
    . Synthesis and biological evaluation of technetium-99m MAG3 as a Hippuran replacement. J Nucl Med. 1986;27:111–116.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    1. Shikano N,
    2. Kanai Y,
    3. Kawai K,
    4. Ishikawa N,
    5. Endou H
    . Transport of 99mTc-MAG3 via rat renal organic anion transporter 1. J Nucl Med. 2004;45:80–85.
    OpenUrlAbstract/FREE Full Text
  31. 31.↵
    1. Despopoulos A
    . A definition of substrate specificity in renal transport of organic anions. J Theor Biol. 1965;8:163–192.
    OpenUrlCrossRefPubMed
  32. 32.↵
    1. Coveney JR,
    2. Robbins MS
    . Comparison of technetium-99m MAG3 kit with HPLC-purified technetium-99m MAG3 and OIH in Rats. J Nucl Med. 1987;28:1881–1887.
    OpenUrlAbstract/FREE Full Text
  33. 33.↵
    1. Jafri RA,
    2. Britton KE,
    3. Nimmon CC,
    4. et al
    . Technetium-99m MAG3, a comparison with iodine-123 and iodine-131 orthoiodohippurate, in patients with renal disorders. J Nucl Med. 1988;29:147–158.
    OpenUrlAbstract/FREE Full Text
  34. 34.↵
    1. Chauser BM,
    2. Hudson FR,
    3. Law MP
    . Renal function in the rat following irradiation. Radiat Res. 1976;67:86–97.
    OpenUrlCrossRefPubMed
  • Received for publication February 12, 2010.
  • Accepted for publication September 13, 2010.
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 52 (1)
Journal of Nuclear Medicine
Vol. 52, Issue 1
January 1, 2011
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Synthesis and In Vivo Evaluation of p-18F-Fluorohippurate as a New Radiopharmaceutical for Assessment of Renal Function by PET
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Synthesis and In Vivo Evaluation of p-18F-Fluorohippurate as a New Radiopharmaceutical for Assessment of Renal Function by PET
Vibhudutta Awasthi, Gopal Pathuri, Hrushikesh B. Agashe, Hariprasad Gali
Journal of Nuclear Medicine Jan 2011, 52 (1) 147-153; DOI: 10.2967/jnumed.110.075895

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Synthesis and In Vivo Evaluation of p-18F-Fluorohippurate as a New Radiopharmaceutical for Assessment of Renal Function by PET
Vibhudutta Awasthi, Gopal Pathuri, Hrushikesh B. Agashe, Hariprasad Gali
Journal of Nuclear Medicine Jan 2011, 52 (1) 147-153; DOI: 10.2967/jnumed.110.075895
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • Acknowledgments
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • Noninvasive Evaluation of Cellular Proliferative Activity in Brain Neurogenic Regions in Rats under Depression and Treatment by Enhanced [18F]FLT-PET Imaging
  • Role of (Drug) Transporters in Imaging in Health and Disease
  • Google Scholar

More in this TOC Section

  • A Realistic Multiregion Mouse Kidney Dosimetry Model to Support the Preclinical Evaluation of Potential Nephrotoxicity of Radiopharmaceutical Therapy
  • Neurovascular Uncoupling: Multimodal Imaging Delineates the Acute Effects of 3,4-Methylenedioxymethamphetamine
  • Deep Learning–Based Attenuation Correction Improves Diagnostic Accuracy of Cardiac SPECT
Show more Basic Science Investigation

Similar Articles

SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire